XTNT
Xtant Medical Holdings, Inc.
+0.01 (+1.66%)0.33USD66.8K成交股數45.6M市值–本益比(近四季)0.4股價營收比-35.0%營收年增(近四季)2026-11-10下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 23.0M-35% | 20.9M-37% | 32.4M+16% | 33.3M+11% | 35.4M+27% | 32.9M+17% | 27.9M+12% | 29.9M+48% | 27.9M | 28.1M | 25.0M | 20.2M |
| 營業成本 | 9.7M | 8.9M | 14.6M | 11.3M | 11.1M | 12.7M | 11.6M | 11.4M | 10.6M | 11.0M | 9.7M | 7.8M |
| 毛利 | 13.3M-45% | 12.0M-41% | 17.8M+9% | 22.0M+18% | 24.3M+40% | 20.2M+18% | 16.3M+6% | 18.6M+49% | 17.3M | 17.1M | 15.3M | 12.5M |
| 毛利率 | 57.9% | 57.3% | 54.9% | 66.1% | 68.6% | 61.5% | 58.4% | 62.1% | 62.1% | 61.0% | 61.3% | 61.6% |
| 研發費用 | 695K | 435K | 459K | 634K | 566K | 443K | 701K | 636K | 527K | 492K | 490K | 180K |
| 銷售管理費用 | 6.4M | 6.3M | 7.3M | 7.1M | 7.5M | 7.5M | 7.5M | 7.7M | 7.8M | 8.9M | 7.1M | 5.0M |
| 營業利益 | −9.2M-298% | −2.9M-375% | −944K-75% | 2.5M-186% | 4.6M-233% | 1.1M-128% | −3.8M+12% | −2.9M+112% | −3.5M | −3.8M | −3.4M | −1.4M |
| 營業利益率 | -39.8% | -14.0% | -2.9% | 7.6% | 13.1% | 3.2% | -13.5% | -9.8% | -12.4% | -13.5% | -13.5% | -6.9% |
| 稅後淨利 | −9.4M-365% | −3.1M-5426% | −4.9M-2% | 1.3M-134% | 3.6M-181% | 58K-101% | −5.0M-154% | −3.9M+76% | −4.4M | −5.0M | 9.2M | −2.2M |
| 淨利率 | -40.9% | -14.8% | -15.2% | 3.9% | 10.0% | 0.2% | -18.0% | -12.9% | -15.8% | -17.7% | 36.9% | -10.8% |
| 稀釋 EPS | -0.07-450% | -0.02 | 0.00-100% | 0.01-133% | 0.02-167% | 0.00-100% | -0.04-157% | -0.03+50% | -0.03 | -0.02 | 0.07 | -0.02 |
| 稀釋股數 | 140M | 140M | 150M | 150M | 149M | 143M | 135M | 130M | 130M | 127M | 136M | 109M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 9.9M | 12.1M | 17.1M | 10.4M | 6.9M | 5.0M | 6.6M | 5.4M | 4.5M | 5.7M | 8.7M | 4.1M |
| 應收帳款 | 19.4M | 17.2M | 17.8M | 25.5M | 27.0M | 23.5M | 20.5M | 21.2M | 21.5M | 21.7M | 19.2M | 13.7M |
| 存貨 | 33.3M | 31.9M | 30.3M | 40.7M | 40.1M | 38.8M | 41.9M | 40.5M | 38.7M | 36.9M | 34.3M | 20.4M |
| 總資產 | 79.7M | 78.0M | 94.1M | 106M | 103M | 95.8M | 98.9M | 95.6M | 93.9M | 92.6M | 92.0M | 65.2M |
| 有息負債 | 7.3M | 8.1M | 11.0M | 17.4M | 22.3M | 22.2M | 19.1M | 21.8M | 16.8M | 17.2M | 14.4M | 16.4M |
| 總負債 | 39.7M | 29.4M | 43.2M | 55.9M | 55.0M | 52.0M | 53.2M | 50.6M | 46.3M | 41.3M | 37.3M | 34.3M |
| 股東權益 | 40.0M | 48.6M | 51.0M | 50.4M | 48.5M | 43.9M | 45.7M | 45.0M | 47.7M | 51.3M | 54.7M | 31.0M |
| 負債比 | 49.8% | 37.7% | 45.9% | 52.6% | 53.1% | 54.2% | 53.8% | 52.9% | 49.2% | 44.6% | 40.6% | 52.5% |
| 淨現金(現金 − 有息負債) | 2.6M | 4.0M | 6.0M | −7.0M | −15.4M | −17.1M | −12.5M | −16.4M | −12.3M | −11.5M | −5.7M | −12.3M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.1M-265% | – | – | – | 1.3M | – | – | −5.8M | – | – | – |
| 資本支出 | – | 194K | – | – | – | 1.2M | – | – | 773K | – | – | – |
| 自由現金流 | – | −2.3M-2753% | – | – | – | 87K | – | – | −6.5M | – | – | – |
| 折舊攤銷 | – | 534K | – | – | – | 1.1M | – | – | 1.0M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -11.1% | – | – | – | 0.3% | – | – | -23.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 134M
| 美國 | 122M | 91.4% | +16.0% |
|---|---|---|---|
| 美國以外 | 11.5M | 8.6% | -2.3% |
產品／服務2025 年度 · 153M
| Orthobiologics | 72.9M | 47.8% | +9.7% |
|---|---|---|---|
| Spinal Implant | 42.3M | 27.7% | -14.3% |
| License | 18.7M | 12.3% | +1146.5% |
| License Revenue | 18.7M | 12.3% | +1146.5% |
| 產品 小計 | 115M | 75.5% | -0.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 134M | +14.2% | 5K | 0.0% | 0.03 | 10.2M |
| FY2024 | 117M | +28.4% | −16K | -0.0% | -0.12 | −16.0M |
| FY2023 | 91.3M | +57.5% | 660.00 | 0.0% | 0.01 | −11.0M |
| FY2022 | 58.0M | +4.9% | −8.5M | -14.6% | -0.09 | −7.1M |
| FY2021 | 55.3M | +3.6% | −4.8M | -8.8% | -0.06 | −1.7M |
| FY2020 | 53.3M | -17.5% | −7.0M | -13.2% | -0.25 | −2.3M |
| FY2019 | 64.7M | -10.4% | −8.2M | -12.7% | -0.63 | −1.3M |
| FY2018 | 72.2M | – | −70.1M | -97.1% | -5.97 | 588K |